0000950170-24-108577.txt : 20240920 0000950170-24-108577.hdr.sgml : 20240920 20240920212152 ACCESSION NUMBER: 0000950170-24-108577 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240920 FILED AS OF DATE: 20240920 DATE AS OF CHANGE: 20240920 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SINGLETON J MATTHEW CENTRAL INDEX KEY: 0001243514 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37355 FILM NUMBER: 241314492 MAIL ADDRESS: STREET 1: 286 STANWICH ROAD CITY: GREENWICH STATE: CT ZIP: 06830 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viking Therapeutics, Inc. CENTRAL INDEX KEY: 0001607678 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461073877 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-704-4660 MAIL ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 ownership.xml 4 X0508 4 2024-09-20 0001607678 Viking Therapeutics, Inc. VKTX 0001243514 SINGLETON J MATTHEW C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 true false false false true Common Stock, par value $0.00001 per share 2024-09-20 4 M false 10300 1.19 A 19800 D Common Stock, par value $0.00001 per share 2024-09-20 4 S false 10300 69.50 D 9500 D Stock Option (Right to Buy) 1.19 2024-09-20 4 M false 10300 0 D 2018-01-03 2027-01-03 Common Stock 10300 0 D The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. /s/ Michael Morneau, as Attorney-in-Fact 2024-09-20